InvestorsHub Logo
Followers 1
Posts 252
Boards Moderated 0
Alias Born 02/23/2024

Re: None

Thursday, 03/21/2024 8:12:26 AM

Thursday, March 21, 2024 8:12:26 AM

Post# of 6959
The Agreement will cover Jaguar's FDA-approved indication of crofelemer (trade name Mytesi®) for HIV-related diarrhea and all potential crofelemer follow-on indications, including cancer therapy-related diarrhea - the subject of Jaguar's placebo-controlled pivotal Phase 3 OnTarget trial, as well as the rare disease indications short bowel syndrome (SBS) and microvillus inclusion disease (MVID), and any other possible future human indications for crofelemer.
Bullish
Bullish
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent JAGX News